Bromfenac Ophthalmic Solution

Phase 3

Bausch & Lomb (BLCO)

Phase 3

Development Phase

Upcoming Catalysts

Historical Events

Regulatory Approvals

No Catalysts Found

No catalyst events have been recorded for this drug yet.

Competitive Landscape

5 competitors in Pain

LTGOJournavx

VRTXSuzetrigine

Phase 3

JNJAcetaminophen/Naproxen Sodium Fixed Combination

Drug Information

Target Indication

Pain

Clinical Trial

NCT01367249

Last updated: 12/23/2025

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Source: FDA Orange Book

Regulatory Approvals

EMA5/18/2011

Yellox

Treatment of postoperative ocular inflammation following cataract extraction in adults.

View on EMA

Drug Science

Mechanism of action & safety profile

Developer

BLCO

Bausch & Lomb

Ophthalmic Goods•North America•NASDAQ

Related Pipeline

Loteprednol Etabonate Gel (BID)Phase 3

Inflammation

brinzolamide 1% ophthalmic suspensionPhase 3

Glaucoma

0.5% Loteprednol Etabonate Ophthalmic OintmentPhase 3

Ocular Inflammation

BOL-303259-XPhase 3

Ocular Hypertension

BromfenacPhase 3

Postoperative Complications

View full pipeline

Get Catalyst Alerts

Receive weekly digests of upcoming catalysts